

# SENTARA HEALTH PLANS

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**Drug Requested:** select one drug below

<input type="checkbox"/> <b>Iqirvo<sup>®</sup></b> (elafibranor)	<input type="checkbox"/> <b>Ocaliva<sup>®</sup></b> (obeticholic acid)
--	--

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member Sentara #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Name/Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight (if applicable): \_\_\_\_\_ Date weight obtained: \_\_\_\_\_

### **Recommended Dosing and Quantity Limits:**

- Iqirvo<sup>®</sup> - 1 tablet (80 mg) once daily
- Ocaliva<sup>®</sup> - Initial: 1 tablet (5 mg) once daily; if an adequate reduction in alkaline phosphatase and/or total bilirubin has not been achieved after 3 months, increase to 1 tablet (10 mg) once daily (maximum: 10 mg/day)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

### **Initial Authorization: 6 months**

- Member is 18 years of age or older
- Medication is prescribed by or in consultation with a hepatologist or gastroenterologist

(Continued on next page)

- Member must have a confirmed diagnosis of Primary Biliary Cholangitis (PBC) with documentation of at least **ONE** of the following (**must submit medical chart notes and lab test results for documentation**):
  - Anti-mitochondrial antibodies (AMA) titer of 1:40 or higher or a level that is above the laboratory upper limit of normal range, or other primary biliary cholangitis-specific auto-antibodies, including sp100 or gp210, if AMA is negative
  - Histologic evidence of primary biliary cholangitis from a liver biopsy (i.e. nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)
- Member has taken UDCA (ursodiol tablets or capsules) for at least 12 months consecutively with insufficient response to therapy and will continue taking UDCA, or has had life-threatening or clinically significant adverse reaction to UDCA (**must submit documentation of therapy failure or intolerance**)
- Baseline alkaline phosphatase (ALP) level is  $\geq 1.67$  times the upper limit of normal despite compliance with UDCA treatment for 12 months (if tolerated) or without UDCA if not tolerated (**must submit test results from within the last 60 days**)
- Baseline total bilirubin level must be submitted (**must submit test results from within the last 60 days**)
- Member will **NOT** use any of the following while taking the prescribed medication: Iqirvo (elafibranor), Ocaliva (obeticholic acid), Bylvay (odevixibat) or Livmarli (maralixibat)
- Member does **NOT** have any of the following: decompensated cirrhosis (e.g. ascites, variceal bleeding, hepatic encephalopathy), autoimmune hepatitis, primary sclerosing cholangitis, alcoholic liver disease, or non-alcoholic steatohepatitis
- Member has **NOT** received a liver transplant

**Reauthorization: 12 months.** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member continues to meet **ALL** initial authorization criteria
- Member continues to take ursodeoxycholic acid (UDCA) in combination with the requested medication
- Member has experienced a decrease in ALP level of at least 15% as compared to pre-treatment level (**must submit current lab test results**)
- Member has experienced a normalization of total bilirubin levels (**must submit current lab test results**)
- Member has experienced disease response to treatment defined by improved or stabilized clinical signs/symptoms of PBC

**Medication being provided by Specialty Pharmacy – Proprium Rx**

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****